



## Get your CE-certified Medical Device in 6 months



[www.bitop.de](http://www.bitop.de)

Medical Devices and Cosmetics, powered by medEctoin®, a natural extremolyte with clinically proven efficacy. Trusted by millions worldwide.

## Cough & Cold



**medEctoIn® Rhinitis Nasal Spray** is as effective as medicinal Xylometazoline

**medEctoIn® Sicca Nasal Spray** for intensive care of the nasal mucosa to reduce crust formation and support the regeneration process

**medEctoIn® Protect Lozenges** proven to reduce sore throat, hoarseness, and dry cough

**medEctoIn® Mouth & Throat Spray** proven to reduce sore throat, hoarseness, and dry cough with exact application in the throat



## Dermatology

**medEctoIn® Dermatitis Cream** for treatment of atopic dermatitis, reduces all symptoms (redness, swelling, oozing/crusting, itching, and hardening of the skin)

**medEctoIn® Psoriasis Cream** for treatment of psoriasis to reduce scaling, redness, and itching of the skin

## Eye care

**medEctoIn® Sicca Eye Drops** for effective moisturization

**medEctoIn® Sicca Eye Drops + HA** for effective moisturization with hyaluronic acid

**medEctoIn® Inflammation Reducing Eye Drops** for quick symptom reduction like itching, tearing, and irritation within 30 seconds

**medEctoIn® Eye Gel** for intensive and longer moisturization of dry and irritated eyes due to prolonged retention time\*\*\*

\*\*\* Compared to low-viscosity eye drops, based on pre-clinical data





## Allergy

**medEctoIn® Allergy Eye Drops** to treat allergy symptoms as effective as medicinal Azelastine\* within 30 seconds

**medEctoIn® Allergy Nasal Spray** as effective as medicinal Azelastine\*\*

**medEctoIn® Allergy Nasal Spray Forte** with additional natural decongestion effect

\* Based on TOSS (Total Ocular Symptom Score)

\*\* Based on TNSS (Total Nasal Symptom Score)

## Airway Diseases

**medEctoIn® Inhalation Solution** for supportive treatment and symptom alleviation of diseases of the airways

**medEctoIn® Hypertonic Inhalation Solution** for symptomatic treatment of inflammatory airway diseases, e.g. bronchitis or Chronic Obstructive Pulmonary Disease (COPD)



## Intimate care

**medEctoIn® Vaginal Gel** immediately moisturizes dry and irritated vaginal mucosa, relieving vaginal atrophy symptoms such as burning and itching with long-lasting effect



## Oral care

**medEctoIn® Mouth Wash** for the supportive care of mucositis, oral discomfort and dry, sensitive mucosa and gums





Dr. Dieter Hahn (Chairman bitop AG), Eva Galik (CEO bitop AG)




“Our mission is to harness the power of nature and science to create products that protect and enhance people’s health. Nature provides the idea - we add the science.”

**Eva Galik**  
**CEO bitop AG**

## Who is bitop?

bitop is a family-owned company based in Dortmund, Germany with over 30 years of experience in biotechnological research and production. bitop offers high quality medical devices for your brand. We take care of the legal manufacturer responsibilities and support the full regulatory process with our internal experts. All products are made in Germany and trusted by renowned global partners, contributing to better health and well-being worldwide.



## Why partner with us?



Clinically proven efficacy



Safe for long-term use



Shelf ready in 6 months under your brand



High consumer acceptance – over 65 million medEctoin® products sold worldwide



Wide range – Dermatology, Cough & Cold, Allergy, Respiratory Health, Eye Care, and Intimate Care



EU GMP manufacturing & ISO 13485 quality system

## How to license your next product?

### Step 1

Select the right products for your market.

### Step 2

Show your vision and present your business case – we'll review it together.

### Step 3

Once approved, you become part of the bitop B2B network

### Step 4

We support you with marketing materials, artwork, and regulatory approvals.

### Step 5


Launch confidently with our ongoing support.

We handle compliance, artwork, and approvals — so you can focus on growing your business with **globally trusted, clinically proven** products.

# ■ Our medEctoin® Portfolio: Medical Devices and Cosmetics

Launch white-label products under your brand in your chosen market in just a few months and create your competitive edge.

## ■ Indications




## ■ Ingredient: Create or upgrade your own formulations and products

**medEctoin®** is a powerful and technically straightforward ingredient that comes with an extensive package of clinical studies, technical documentation and marketing material. We enable your organization to quickly create and successfully market your own unique formulations and products.

**medEctoin®**  
pharma-grade Ectoin

# ■ The Science of medEctoin®

medEctoin® is a **natural extremolyte** produced by microorganisms in extreme environments. It protects cells, membranes, and proteins from stress factors – helping to keep skin, eyes, and airways healthy.




medEctoin® surrounded by water molecules, forming the medEctoin® Hydro Complex.

## **Water Shell Formation (medEctoin® Hydro Complex):**

medEctoin® forms a hydration shell around cells and biomolecules. This stabilizes moisture levels and strengthens the skin barrier.

## **Stabilization of Cells & Proteins**

It protects cell membranes and proteins from oxidative stress, UV radiation, and allergens – keeping them structurally stable and functional.



Cross-section of the human cell surface with protective medEctoin® Hydro Complex.



Head groups of the lipid bilayer of the cell are stabilized by the medEctoin® Hydro Complex.

## **Anti-Inflammatory & Regenerative Effects**

medEctoin® reduces the release of inflammatory mediators and supports the natural regeneration of skin and mucous membranes.

# medEctoin® Allergy Eye Drops 2%

AAT04



Allergic diseases of the eyes are often characterized by symptoms like red, itchy, and watery eyes. Most topical OTC products used in this indication are pharmaceuticals containing antihistamines or cromoglicic acid with well-known side effects. **medEctoin® Allergy Relief Eye Drops 2%** reduce the allergic conjunctivitis symptoms like red, itchy and watery eyes and are very well tolerated.



## TREATMENT:

Quick reduction of symptoms like itching, tearing and irritation within 30 seconds

Medical device as effective as medicinal Azelastine\*

Alleviates allergic symptoms (red, itchy and watery eyes)

Reduces allergen induced inflammation of the conjunctiva

Efficacy clinically proven\*\*

Isotonic solution with medEctoin®, a natural, cell-protective molecule with inflammation-reducing and membrane-stabilizing properties



## PREVENTION:

Protects against harmful influences of allergens



## REGENERATION:

Supports the regeneration process of irritated and sensitive conjunctiva



## SAFETY & USABILITY:

Suitable for contact lens wearers

Suitable for sensitive eyes

Suitable for children

Preservative free

\*based on a calculated TOSS (total ocular symptom score) rated by physicians within a clinical study. \*\* For formulation AAT04.

## INGREDIENTS:

medEctoin®, Sodium Chloride, Hydroxyethyl Cellulose, Citrate Buffer, Water



## Shelf Life:

SDU: 30 months

MDU: 36 months



## Medical Device Class:

Ila (MDD)



## Packaging:

0.5 ml solution in ampoules (SDU)

10 ml in multi-dose dropper (OSD or 3K\*)

\* For formulation AAT04

## Period after Opening:


SDU: N.a.

MDU: 6 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Allergy Eye Drops 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction in acute allergic conjunctivitis symptoms vs. placebo.	Salapatek et al. 2021
medEctoin® Allergy Eye Drops 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine eye drops in alleviating local allergic eye symptoms.	Werkhäuser et al. 2014
medEctoin® Allergy Eye Drops 2%	N = 50 Non-interventional, randomized, controlled study	Immediate relief within 30 seconds post-CPT exposure; 87% reduction in irritation after 30 minutes.	Clinical study report btph-015-2018-AAT04-EES09

## 30 seconds: Improvement of irritation



**Figure 1:** Quick improvement of eye irritation within 30 seconds (patients' evaluation).

**Reference:** btph-015-2018-AAT04-EES09, unpublished

# medEctoin® Allergy Eye Drops 1%

AAT02



Allergic diseases of the eyes are often characterized by symptoms like red, itchy, and watery eyes. Most topical OTC products used in this indication are pharmaceuticals containing antihistamines or cromoglicic acid with well-known side effects. **medEctoin® Allergy Eye Drops 1%** effectively reduce allergic conjunctivitis symptoms like red, itchy and watery eyes and are very well tolerated.

---



## TREATMENT:

Alleviates allergic symptoms (red, itchy and watery eyes)

Isotonic solution with medEctoin®, a natural, cell-protective molecule with membrane-stabilizing properties.



## PREVENTION:

Protects against harmful influences of allergens



## REGENERATION:

Supports the regeneration process of irritated and sensitive conjunctiva



## SAFETY & USABILITY:

Suitable for contact lens wearers

Suitable for sensitive eyes

Suitable for children

Preservative free

---

## INGREDIENTS:

medEctoin®, Sodium Chloride, Citrate Buffer, Water



## Medical Device Class:

IIa (MDD)



## Packaging:

0.5 ml solution in ampoules (SDU)

10 ml in multi-dose dropper (OSD or 3K)



## Shelf Life:

SDU: 30 months

MDU: 36 months

## Period after Opening:


SDU: N.a.

MDU: 6 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Allergy Eye Drops 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction in acute allergic conjunctivitis symptoms vs. placebo.	Salapatek et al. 2021
medEctoin® Allergy Eye Drops 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine eye drops in alleviating local allergic eye symptoms.	Werkhäuser et al. 2014
medEctoin® Allergy Eye Drops 2%	N = 50 Non-interventional, randomized, controlled study	Immediate relief within 30 seconds post-CPT exposure; 87% reduction in irritation after 30 minutes.	Clinical study report btph-015-2018-AAT04-EES09

## Reduction of allergic conjunctivitis symptoms



**Figure 1:** Significant improvement of allergic conjunctivitis (formulation with 2% medEctoin®).

**Reference:** Salapatek et al. 2021

# medEctoïn® Allergy Nasal Spray 1%

ANS02



Allergic reactions in the nose are often characterized by symptoms like itchy and runny nose, nasal congestion and sneezing. Most OTC products used in this indication are pharmaceuticals containing cromoglicic acid, antihistamines or glucocorticoids with well-known side effects. **medEctoïn® Allergy Nasal Spray 1%** effectively alleviates allergic rhinitis symptoms in a natural way and is very well tolerated.



## TREATMENT:

Alleviates allergic symptoms (itchy and runny nose, sneezing, nasal congestion)



## PREVENTION:

Reduces harmful influences of allergens and airborne particles

Also suitable for preventive use



## REGENERATION:

Supports the regeneration process of irritated nasal mucosa caused by allergens



## SAFETY & USABILITY:

Suitable for children and sensitive noses

No habituation effect

Preservative-free

100% natural

## INGREDIENTS:

medEctoïn®, Sea Salt, Water



## Medical Device Class:

IIa (MDR)



## Packaging:

20 ml in MDU (3K)



## Shelf Life:

36 months


## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEcto <sup>in</sup> <sup>®</sup> Allergy Nasal Spray 2%	N = 46 Double-blind, randomized, placebo- controlled, cross-over study	Significant reduction of acute allergic symptoms, based on Total Nasal Symptom Score evaluation.	Salapatek et al. 2021
medEcto <sup>in</sup> <sup>®</sup> Allergy Nasal Spray 2%	N = 43 Non- interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine nasal spray in alleviating local allergic symptoms in the nose.	Werkhäuser et al. 2014
medEcto <sup>in</sup> <sup>®</sup> Allergy Nasal Spray 2%	N = 50 Non- interventional, comparator-controlled, cross-over study	Superior and significant efficacy compared to cromoglicic acid nasal spray in alleviating local allergic symptoms in the nose.	Clinical study report btph-015- 2018-AAT04-EES09

## Reduction of allergic rhinitis symptoms



**Figure 1:**  
Symptom relief of Single Nasal Scores  
(Formulation: medEcto<sup>in</sup><sup>®</sup> Allergy Nasal Spray 2%)

**Reference:**  
Werkhäuser et al. 2014

# medEcto<sup>in</sup>® Allergy Nasal Spray 2%

ANS03



Allergic reactions in the nose are often characterized by symptoms like itchy and runny nose, nasal congestion and sneezing. Most OTC products used in this indication are pharmaceuticals containing cromoglicic acid, antihistamines or glucocorticoids with well-known side effects. **medEcto<sup>in</sup>® Allergy Nasal Spray 2%** effectively alleviates allergic rhinitis symptoms in a natural way and is very well tolerated.



## TREATMENT:

Alleviates allergic symptoms (itchy and runny nose, sneezing, nasal congestion)

Reduces allergen induced inflammation of the nasal mucosa

Slightly hypertonic nasal spray with medEcto<sup>in</sup>®, a natural, cell-protective molecule with inflammation-reducing and membrane-stabilizing properties



## PREVENTION:

Reduces harmful influences of allergens and airborne particles

Also suitable for preventive use



## REGENERATION:

Supports the regeneration process of irritated nasal mucosa caused by allergens



## SAFETY & USABILITY:

Suitable for children

No habituation effect

Suitable for sensitive noses

Preservative-free

## INGREDIENTS:

medEcto<sup>in</sup>®, Sea Salt, Water



## Medical Device Class:

IIa (MDR)



## Packaging:

20 ml in MDU (3K)



## Shelf Life:

36 months


## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Allergy Nasal Spray 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction of acute allergic symptoms, based on Total Nasal Symptom Score evaluation.	Salapatek et al. 2021
medEctoin® Allergy Nasal Spray 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine nasal spray in alleviating local allergic symptoms in the nose.	Werkhäuser et al. 2014
medEctoin® Allergy Nasal Spray 2%	N = 50 Non-interventional, comparator-controlled, cross-over study	Superior and significant efficacy compared to cromoglicic acid nasal spray in alleviating local allergic symptoms in the nose.	Clinical study report btph-015-2018-AAT04-EES09

## Reduction of allergic rhinitis symptoms



**Figure 1:**  
Symptom relief of Single Nasal Scores  
(Formulation: medEctoin® Allergy Nasal Spray 2%)

**Reference:**  
Werkhäuser et al. 2014

# medEcto<sup>in</sup>® Allergy Nasal Spray Forte

ANS07



Allergic reactions in the nose are often characterized by symptoms like itchy and runny nose, nasal congestion and sneezing. Most OTC products used in this indication are pharmaceuticals containing cromoglicic acid, antihistamines, or glucocorticoids with well-known side effects. **medEcto<sup>in</sup>® Allergy Nasal Spray Forte** effectively alleviates allergic rhinitis symptoms in a natural way with decongestant properties and is very well tolerated.



## TREATMENT:

- Decongests the nose in a natural way
- Alleviates allergic symptoms (itchy and runny nose, sneezing, nasal congestion)
- Reduces allergen induced inflammation of the nasal mucosa
- Hypertonic nasal spray with medEcto<sup>in</sup>®, a natural, cell-protective molecule with inflammation-reducing and membrane-stabilizing properties



## PREVENTION:

- Reduces harmful influences of allergens and airborne particles
- Also suitable for preventive use



## SAFETY & USABILITY:

- Suitable for children
- No habituation effect
- Suitable for sensitive noses
- Preservative-free



## REGENERATION:

- Supports the regeneration process of irritated nasal mucosa caused by allergens

## INGREDIENTS:

medEcto<sup>in</sup>®, Sea Salt, Water



## Medical Device Class:

IIa (MDR)



## Packaging:

20 ml in MDU (3K)



## Shelf Life:

36 months


## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoïn® Allergy Nasal Spray 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction of acute allergic symptoms, based on Total Nasal Symptom Score evaluation.	Salapatek et al. 2021
medEctoïn® Allergy Nasal Spray 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine nasal spray in alleviating local allergic symptoms in the nose.	Werkhäuser et al. 2014
medEctoïn® Allergy Nasal Spray 2%	N = 50 Non-interventional, comparator-controlled, cross-over study	Superior and significant efficacy compared to cromoglicic acid nasal spray in alleviating local allergic symptoms in the nose.	Clinical study report btph-015-2018-AAT04-EES09

## Reduction of allergic rhinitis symptoms



**Figure 1:**  
Symptom relief of Single Nasal Scores  
(Formulation: medEctoïn® Allergy Nasal Spray 2%).

**Reference:**  
Werkhäuser et al. 2014

# medEctoïn® Allergy Relief Lozenges

EHT16/17



The common allergy treatments focus solely on the nose and eyes. But allergy patients don't only suffer there. The mouth and throat are also severely strained by the harmful allergens. An itchy palate and hoarseness caused by the persisting need to clear the throat are common side effects of allergies. The **medEctoïn® Allergy Relief Lozenges** effectively reduce these oral allergic symptoms.

---



## TREATMENT:

Reduce typical allergic symptoms in mouth and throat like sore throat or itchy palate

Form a natural and moisturizing protective shield on irritated mucous membranes in mouth and throat

Lozenges with medEctoïn®, a natural, cell-protective molecule with inflammation-reducing and membrane-stabilizing properties



## PREVENTION:

Stabilize the cell membranes of the mucosa in mouth and throat and prevent irritations

Recommended to start usage before an expected allergen exposure



## SAFETY & USABILITY:

Effects based on 100% natural ingredients

Preservative-free

Sugar-free

Suitable for patients allergic to e.g. airborne allergens like pollen, house dust or animal hair

Suitable for children over 6 years



## FLAVOURS:

Honey Lemon and Mint

Forest Berry and Cherry

## INGREDIENTS:

### Honey Lemon and Mint:

medEctoïn®, Isomalt, Sucralose, Menthol, Citric Acid, Lemon Mint Flavour, Honey Flavour, Safflower Concentrate, Glucose Syrup, Water

### Forest Berry and Cherry:

medEctoïn®, Isomalt, Sucralose, Citric Acid, Cherry Flavour, Forest Berry Flavour, Black Mulberry Flavour, Anthocyanin (Black Carrot), Water



## Medical Device Class:

I (MDD)



## Shelf Life:

24 months

## Period after Opening:

N.a.




## Packaging:

1, 2, 3 or 4 blister strips containing 8 lozenges à 2.3 g

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Allergy Lozenges	N = 89 Multi-center, prospective, randomized, controlled study	Significant reduction of all oropharyngeal allergy symptoms shown for preventive (41%) and therapeutic (54%) treatment	Khachouk et al. 2022
medEctoin® Protect Lozenges	N = 102 Non-interventional, comparator-controlled clinical study	86% of patients reported symptom improvement. Faster relief: medEctoin® Lozenges significantly outperformed the comparator in the first 5 days.	btph-014-2018-EHT02

## Improvement of patients' general condition



**Figure 1:** Significant reduction of oropharyngeal allergy symptoms.

**Reference:** Khachouk et al. 2022

# medEctoïn® Rhinitis Nasal Spray

SNS01



A blocked or runny nose, sneezing and facial pain are caused by inflammation of the nasal and sinus mucosa. These symptoms are typically treated with drug-based nasal decongestants, which are associated with well-known side effects. **medEctoïn® Rhinitis Nasal Spray** works as effectively as common decongesting nasal sprays (with e.g. Xylometazoline). It reduces typical symptoms of a common cold and supports the regeneration process of irritated nasal mucosa without a habituation effect.



## TREATMENT:

Clinically proven to work as effective as common decongesting nasal spray drugs (with e.g. Xylometazoline)

4-in-1 effect: Significantly reduces blocked nose, runny nose, facial pain/ headache and loss in smell and taste

Effectively decongests the nose and sinuses in a natural way

Reduces inflammation of disturbed nasal mucosa and sinuses caused by rhinitis and rhinosinusitis (common cold)

Alleviates typical symptoms such as dry and wound nasal epithelium, sneezing, itching and crust formation

Reduces negative side effects of common decongesting nasal sprays, e.g. the dehydration of the nasal mucous membranes



## PREVENTION:

Reduces the need for pharmaceutical decongestant sprays (e.g. with Xylometazoline)

The medEctoïn® Hydro Complex and the stabilized mucosal barrier structure help to reduce viral ingressión\*

Cleans and moisturizes the nasal mucosa



## REGENERATION:

Supports the regeneration process of irritated nasal mucosa



## SAFETY & USABILITY:

Suitable for children over 3.5 kg body weight

No habituation effect

Preservative-free

\*based on pre-clinical data

## INGREDIENTS:

medEctoïn®, Sea Salt, Water, Phosphate Buffer



## Shelf Life:

36 Months



## Medical Device Class:

IIa (MDR)



## Packaging:

20 ml in MDU bottle (3K)


## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoïn® Rhinitis Nasal Spray	N = 168 Multi-center, non-interventional, comparator-controlled study	Effectively relieves rhinitis symptoms by approx. 65%, with comparable efficacy to Xylometazoline. Significant improvement of nasal mucosa dryness.	Werkhäuser et al. 2021
medEctoïn® Rhinitis Nasal Spray	N = 65 Multi-center, comparator-controlled study	Significant reduction of primary symptoms of acute rhinosinusitis.  Comparable efficacy to Phytotherapeutic dragees for the treatment of sinusitis.	Eichel et al. 2013

## Physicians' assessment of symptom improvement and tolerability



**Figure 1:** Symptom improvement and tolerability of medEctoïn® Rhinitis Nasal Spray compared to Xylometazoline Nasal Spray.

**Reference:** Werkhäuser et al. 2021

# medEcto<sup>®</sup> Sicca Nasal Spray

BNS01



Dryness of mucous membranes in the nose (rhinitis sicca anterior) is characterized by inflammation of the nasal tissue resulting in painful symptoms such as burning, itching and crust formation. Most nasal sprays used in this indication contain sea salt or herbal ingredients that provide moisture. **medEcto<sup>®</sup> Sicca Nasal Spray** combines the membrane-stabilizing and inflammation-reducing molecule medEcto<sup>®</sup> with well-known sea salt to treat rhinitis sicca anterior in an effective way.



## TREATMENT:

- Alleviates typical symptoms of the dry nose syndrome (crust formation, itching in the nose)
- Concomitant treatment of nasal obstruction
- Reduces inflammation caused by disturbed and dry nasal mucosa



## PREVENTION:

- Prevents from further dehydration
- Gently cleans nasal cavities
- Also suitable for the preventive use



## REGENERATION:

- Provides essential moisture to dry and irritated noses
- Supports the regeneration process of irritated nasal mucous membranes



## SAFETY & USABILITY:

- Suitable for children
- No habituation effect
- Preservative-free

## INGREDIENTS:

medEcto<sup>®</sup>, Sea Salt, Water and Phosphate Buffer



## Shelf Life:

36 months



## Medical Device Class:

I (MDD)



## Packaging:

20 ml in MDU bottle (3K or APF)


## Period after Opening:

6 weeks

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Nasal Spray	N = 50 open label, non-interventional, single arm study	Significant improvement of symptom scores for nasal breathing obstruction, crust formation, blood deposits, and secretion's viscosity.	Sonnemann et al. 2014A

## Improvement of symptom score



**Figure 1:**

Development of rhinitis sicca symptoms after 7 and 14 days of treatment.

**Reference:**

Sonnemann et al. 2014A

# medEctoïn® Protect Lozenges

EHT11/12/14



Irritations in the mouth and throat are caused by multiple factors such as voice overuse, air conditioning or a common cold. The most common symptoms are sore throat, hoarseness and pain on swallowing. The **medEctoïn® Protect Lozenges** hydrate the irritated mucous membranes and help to prevent irritations and reduce inflammation. The lozenges are the perfect companion to keep your throat and voice smooth throughout the day.



## TREATMENT:

Reduce symptoms of acute Pharyngitis, such as hoarseness, sore throat, and pain on swallowing

Reduce inflammation and stabilizes the mucous membranes in mouth and throat

Soothe irritations and alleviate the urge to cough

Form a protective shield called "medEctoïn® Hydro Complex" on mucous membranes in mouth and throat



## PREVENTION:

Reduce the danger of a bacterial or viral infection in the mouth and throat

Reduce and prevent irritations of the mucous membranes such as voice fatigue, tickly throat, or dryness caused by voice overuse, allergens or dry air resulting from e.g. heating, cold, air conditioning, or smoke

Recommended to start usage at the first signs of hoarseness, dry cough and a sore throat

Relieve first symptoms such as hoarseness, dry cough and a sore throat and prevent worsening



## REGENERATION:

Hydrate dry and irritated epithelia and support their regeneration

Increase saliva production and support free breathing



## SAFETY & USABILITY:

Effects based on 100% natural ingredients

Preservative-free

Sugar-free

Suitable for children over 6 years



## FLAVOURS:

Honey Lemon and Mint

Honey and Salt (Mucolytic properties: dissolves thick and compact mucous)

Forest Berry and Cherry

## INGREDIENTS:

**Honey Lemon and Mint:** medEctoïn®, Isomalt, Sucralose, Menthol, Citric Acid, Lemon Mint Flavour, Honey Flavour, Safflower Concentrate, Glucose Syrup, Water

**Honey Salt:** medEctoïn®, Isomalt, Sucralose, Sodium Chloride, Honey Flavour, Safflower Concentrate, Glucose Syrup, Water

**Forest Berry and Cherry:** medEctoïn®, Isomalt, Sucralose, Citric Acid, Cherry Flavour, Forest Berry Flavour, Black Mulberry Flavour, Anthocyanin (Black Carrot), Water



## Medical Device Class:

I (MDD)



## Shelf Life:

24 months

## Period after Opening:

N.a.




## Packaging:

1, 2, 3 or 4 blister strips containing 8 lozenges à 2.3 g

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Protect Lozenges	N = 102 Non-interventional, comparator-controlled clinical study	86% of patients reported symptom improvement. Faster relief: medEctoin® Lozenges significantly outperformed the comparator in the first 5 days.	btph-014-2018-EHT02
medEctoin® Soft Lozenges	N = 90 prospective, active-controlled clinical study	Significant reduction in acute pharyngitis symptoms. Significant superiority compared to Hyaluronic Acid Lozenges.	Dao et al. 2019

## Improvement of patients' general condition



**Figure 1:** Significant better improvement of patient's general condition with medEctoin® Lozenges than with the comparator.

**Reference:** btph-014-2018-EHT02

# medEctoïn® Soft Lozenges

EHT01/04



Irritations in the mouth and throat are caused by multiple factors such as voice overuse, air conditioning or a common cold. The most common symptoms are sore throat, hoarseness and pain on swallowing. The **medEctoïn® Soft Lozenges** hydrate the irritated mucous membranes and help to prevent irritations and reduce inflammation. The lozenges are the perfect companion to keep the throat and voice smooth throughout the day.



## TREATMENT:

Relieve hoarseness, sore throat, or pain on swallowing

Reduce inflammation of the mucous membranes in mouth, throat and larynx

Alleviate the urge to cough

Form a protective shield called "medEctoïn® Hydro Complex" on mucous membranes in mouth and throat

Stabilize the mucous membranes



## PREVENTION:

Relieve first symptoms such as hoarseness, dry cough and a sore throat and prevent worsening

Reduce and prevent irritations of the mucous membranes such as voice fatigue, tickly throat, or dryness

Recommended to start usage at the first signs of hoarseness, dry cough and a sore throat



## REGENERATION:

Hydrate dry and irritated epithelia and supports their regeneration

Increase saliva production



## SAFETY & USABILITY:

Effects based on 100% natural ingredients

Preservative-free

Sugar-free

Suitable for children over 6 years



## FLAVOURS:

Wildberry

Honey Lemon

## INGREDIENTS:

**Wildberry:** medEctoïn®, Wildberry Flavour, Menthol, Grape Skin Extract, Citric Acid, Acesulfame K, Gum Arabic, Maltitol, Sorbitol, Water, Vegetable Oil and Agent Beeswax

**Honey Lemon:** medEctoïn®, Honey Flavour, Lemon Oil\*, Lemon Yellow Colour\*\*, Citric Acid, Acesulfame K, Gum Arabic, Maltitol, Sorbitol, Water, Vegetable Oil and Agent Beeswax.

\*From natural origin

\*\*may contain traces of apple & safflower



## Medical Device Class:

Ia (MDD)



## Shelf Life:

36 months

## Period after Opening:

N.a.




## Packaging:

2, 3 or 4 blister strips containing 10 lozenges à 1g

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Soft Lozenges	N = 90 prospective, active-controlled clinical study	Significant reduction in acute pharyngitis symptoms. Significant superiority compared to Hyaluronic Acid Lozenges.	Dao et al. 2019
medEctoin® Protect Lozenges	N = 102 Non-interventional, comparator-controlled clinical study	86% of patients reported symptom improvement. Faster relief: medEctoin® Lozenges significantly outperformed the comparator in the first 5 days.	btph-014-2018-EHT02

## Improvement of symptoms after 7 days



**Figure 1:** Improvement of pharyngitis symptoms after 7 days of treatment.

**Reference:** Dao et al. 2019

# medEctoïn® Mouth and Throat Spray

ERS03/04



A common cold often comes along with an inflamed and irritated throat. Mucous membranes are swollen and red which causes pain on swallowing. Moreover, the irritation causes dry cough and hoarseness. **medEctoïn® Mouth & Throat Spray** effectively reduces symptoms like sore throat, hoarseness, dry cough and pain on swallowing. Moreover, it hydrates the dry and irritated epithelia and supports the regeneration process.



## TREATMENT:

Reduces symptoms of acute Pharyngitis and/or Laryngitis, such as sore throat, hoarseness, cough, and pain on swallowing

Supports the reduction of inflammation of the mucous membranes in mouth and throat

Reduces the duration of a sore throat/ hoarseness

Recommended to start usage at the first signs of hoarseness, dry cough, swollen lymph nodes and a sore throat.



## PREVENTION:

The medEctoïn® Hydro Complex and the stabilized mucosal barrier structure help to reduce bacterial, viral and allergen ingressión\*

Relieves first symptoms such as hoarseness, dry cough, swollen lymph nodes and a sore throat and prevents worsening



## REGENERATION:

Hydrates dry and irritated epithelia and supports regeneration by stabilization of mucosal barrier structure



## SAFETY & USABILITY:

Effect is based on 100% natural ingredients

Preservative free

Suitable for children over 2 years



## FLAVOURS:

Mint

Salvia

\*based on pre-clinical data

## INGREDIENTS:

**Mint:** medEctoïn®, Sea Salt, Phosphate Buffer, Mint Oil, Xylitol, Water

**Salvia:** medEctoïn®, Sea Salt, Phosphate Buffer, Xylitol, Sodium Cyclamate, Caprylic Acid, Mint Oil, Salvia Oil, Water



## Medical Device Class:

IIb (MDR)



## Shelf Life:

36 Months

## Period after Opening:

3 months




## Packaging:

20 ml in MDU bottle (3K)

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Mouth and Throat Spray	N = 95 non-interventional prospective controlled, multi-center study	Superior efficacy in treating acute pharyngitis and/ or laryngitis compared to mineral salt pastilles (Emser® Pastillen)	Müller et al. 2016

## Improvement of Pharyngitis symptoms



**Figure 1:** Improvement of pharyngitis symptom score (swollen palatine tonsils, swollen cervical lymph nodes, fever, and cough).

**Reference:** Müller et al. 2016

# medEctoin® Inhalation Solution

EIL07



Acute bronchitis, asthma and chronic obstructive pulmonary disease are widespread diseases with increasing incidences. Depending on the condition, patients are treated with pharmaceuticals which can have severe side effects or ordinary saline solutions that might lack efficacy. The patent-protected **medEctoin® Inhalation Solution** combines preventive and therapeutic properties. It dilutes **tenacious** mucus, facilitates expectoration and helps to prevent symptoms induced by allergens or airborne particles (e.g. particulate matter).

---



## TREATMENT:

For supportive treatment and symptom alleviation of diseases of the airways, such as allergic or non-allergic asthma, bronchitis or Chronic Obstructive Pulmonary Disease (COPD)

Protects and moisturizes the mucosa of the airways (e.g. when exposed to particulate matter, pollen, dust or to dry air in heated or air-conditioned rooms)



## PREVENTION:

Prevents drying of the mucous membranes, dilutes tenacious mucus so that it can be coughed-up more easily

Prevents symptoms of allergic reactions of the respiratory system while suffering from e.g. allergic asthma, house-dust allergy, etc.

Prevents bronchitis symptoms



## SAFETY & USABILITY:

Suitable for children

For administration with jet, mesh and ultrasound nebulizers

---

## INGREDIENTS:

medEctoin®, Sea Salt, Water.



## Medical Device Class:

IIa (MDD)



## Packaging:

2.5 ml in SDU



## Shelf Life:

SDU: 36 months

## Period after Opening:

SDU: N.a.

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Inhalation Solution	N = 135 Prospective, controlled, observational, multicenter study	Significant reduction of bronchitis symptoms. Slightly superior improvement vs. Saline Solution.	Tran et al. 2019
medEctoin® Inhalation Solution	N = 18 Double-blind, randomized, placebo-controlled, crossover study	Significant improvement in lung function parameters. Best efficacy observed at 1.3 % dose, including a decrease of exhaled nitric oxide.	Kappeler et al. 2011
medEctoin® Inhalation Solution	N = 36 Double-blind, randomized, placebo-controlled, crossover study.	Significant reduction of nitrogen oxides indicates reduced airway inflammation and potential improvement in respiratory symptoms.	Unfried et al. 2016

## Baseline-adjusted symptoms scores




Figure 1: Improvement of bronchitis symptoms

Reference: Tran et al. 2019

# medEctoin® Hypertonic Inhalation Solution

EIL15



The medEctoin® Hypertonic Inhalation Solution is a 3% saline solution with 0.65% medEctoin®, designed to support the natural clearance mechanisms of the respiratory tract. It moisturizes the airway mucosa, prevents dryness, and helps loosen and dilute thick mucus, thereby facilitating its mobilization and expectoration. By improving mucus clearance, it contributes to the relief of airway obstruction and respiratory discomfort associated with inflammation or excessive mucus buildup.



## TREATMENT:

Symptomatic treatment of inflammatory airway diseases, e.g. bronchitis, asthma or Chronic Obstructive Pulmonary Disease (COPD)

Treats bronchitis symptoms, e.g. cough, mucus production, chest pain

Dilutes thick mucus and makes it easier to cough-up

Mobilizes mucus in the upper and lower airways

Supports mucus clearance



## PREVENTION:

Prevents bronchitis symptoms, e.g. cough, mucus production, chest pain

Prevents the mucous membranes from drying out



## SAFETY & USABILITY:

Can be used with all common nebulizers

Efficacy clinically proven

## INGREDIENTS:

medEctoin®, Sea Salt, Water.



## Medical Device Class:

IIb (MDR)



## Packaging:

2.5 ml in SDU



## Shelf Life:

≥24 months (target: 36 months)

## Period after Opening:

SDU: N.a.

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Inhalation Solution	N = 135 Prospective, controlled, observational, multicenter study	Significant reduction of bronchitis symptoms. Slightly superior improvement vs. Saline Solution.	Tran et al. 2019
medEctoin® Inhalation Solution	N = 18 Double-blind, randomized, placebo-controlled, crossover study	Significant improvement in lung function parameters. Best efficacy observed at 1.3 % dose, including a decrease of exhaled nitric oxide.	Kappeler et al. 2011
medEctoin® Inhalation Solution	N = 36 Double-blind, randomized, placebo-controlled, crossover study.	Significant reduction of nitrogen oxides indicates reduced airway inflammation and potential improvement in respiratory symptoms.	Unfried et al. 2016

## Baseline-adjusted symptoms scores




Figure 1: Improvement of bronchitis symptoms

Reference: Tran et al. 2019

# medEctoin® Acute Cream 7%

EHK25



During flare-up phases of atopic dermatitis or other inflammatory dermatoses, patients suffer from red, itchy, dry, and rough skin. **medEctoin® Acute Cream 7%** is clinically proven to reduce skin redness and itching. With its excellent safety profile, it is suitable for use on children +1 months and for long-term application.



## TREATMENT:

Reduces itching by 71%<sup>2</sup>

Reduces skin redness and scratching in atopic dermatitis

Reduces the extent and severity of atopic dermatitis by up to 50%<sup>1</sup>

Can be used for symptom treatment of acute flare-ups

Can be used in combination with topical corticosteroids during the phases of flare-ups

The combination with topical corticosteroids is up to 80% more effective than treatment with corticosteroids alone <sup>2</sup>

Skin moisture is improved by 60% after just one hour<sup>3</sup>

Reduces dryness by increasing skin moisture content and therefore smoothens the skin

Effective and safe as monotherapy for the treatment of symptoms of mild-to-moderate atopic dermatitis



## PREVENTION:

Protects the skin's immune system and prevents UVA-induced skin aging and damage



## REGENERATION:

Helps to relieve and calm irritated and damaged skin by reducing inflammatory reactions and supporting the regeneration process

Repairs the impaired skin barrier with enhanced hydration



## SAFETY & USABILITY:

97% of patients confirm the effectiveness<sup>3</sup>

Suitable for long-term application/ daily use

Suitable for infants and children

<sup>1</sup> Marini et al. 2014

<sup>2</sup> Kauth M., Trusova OV. 2022

<sup>3</sup> T. Dirschka; unpublished study btph-043-2019\_EHK02

## INGREDIENTS:

medEctoin®, Aqua, Hydrogenated Lecithin, Ceramide-3, Squalane, Olea Europaea Fruit Oil, Caprylic/Capric Triglyceride, Butyrospermum Parkii Butter, Oryza Sativa (Rice) Bran Cera, Carbomer, Xanthan Gum, Sodium Carbomer, Glycine, Alanine, Pentylene Glycol, Butylene Glycol, Hydroxyethylcellulose, Glycerine, Hydroxyphenyl Propamidobenzoic Acid



## Medical Device Class:

Ila (according to 93/42/EEC)



## Shelf Life:

36 Months

## Period after Opening:

3 months

(Aluminium Tube and Airless Dispenser)

N.a. (Sachet)



## Packaging:

Aluminium Tube (5, 30, 50 ml)


Airless Dispenser (30, 50 ml)

Sachets (2 ml)

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Dermatitis Cream 7%	N = 65 Comparator-controlled, double-blind, multicenter clinical study	Up to 50% improvement of atopic dermatitis symptoms. SCORAD: Superior performance over active comparator.	Marini et al. 2014
medEctoin® Dermatitis Cream 7%	N = 30 Prospective, observational, single-arm clinical study	Significant improvement of atopic dermatitis severity and quality of life over 4 weeks.	Hon et al. 2019
medEctoin® Dermatitis Cream 7%	N = 50 Open-label, controlled, prospective stud	Significant reduction of atopic dermatitis symptoms in children using medEctoin® Cream as part of a comprehensive treatment regimen.	Kudryavtseva et al. 2019

## Improvement of Atopic Dermatitis



**Figure 1:** Improvement of Atopic Dermatitis symptoms by up to 50%.

**Reference:** Marini et al. 2014.

# medEctoin® Psoriasis Cream 5%

EHK16



Patients that suffer from psoriasis struggle not only with skin plaques and redness. Itchy skin is one of the most troublesome symptoms of this disease. However, studies have shown that itching is nearly not influenced by standard therapies with vitamin D- or steroid-containing creams. The unique combination of medEctoin® and Urea in the **medEctoin® Psoriasis Cream** supports the natural elimination of dead cells from the skin surface and reduces scaling, itching, redness, roughness and hardening of the skin.



## TREATMENT:

Reduces scaling, itching, redness, roughness and hardening of the skin

Supports the natural elimination of dead cells from the skin surface which is a symptom of psoriasis



## PREVENTION:

Moisturizes the skin and prevents further dehydration

Stabilizes the skin barrier



## REGENERATION:

Supports the skin's own repair mechanism

Relieves and calms irritated and damaged skin by reducing inflammatory reactions and supporting the regeneration process

Helps to normalize the skin cell production and maturation time of the skin



## SAFETY & USABILITY:

Suitable for infants and children

Suitable for sensitive skin and long-term treatment/ daily use

Free from fragrances, dyestuffs and preservatives

Steroid-free

## INGREDIENTS:

medEctoin®, Aqua, Urea, Cetearyl Alcohol, Cetearyl Isononanoate, Glycerin, Simmondsia Chinensis Seed Oil, Hydrogenated Polydecene, Pentylene Glycol, Hydroxyethyl Urea, Panthenol, Cetearyl Glucoside, Lecithin, Allantoin, Xanthan Gum, Ethylhexylglycerin, Sodium Lactate, Sodium Cetearyl Sulfate, Triacetin



## Shelf Life:

30 months

## Period after Opening:

6 months



## Packaging:

Aluminium Tube 5, 30, 50 ml




## Medical Device Class:

Ila (MDD)

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Psoriasis Cream	N = 94 Prospective, observational clinical study	Significant improvement of Psoriasis symptoms by 79%.  82% of patients rated the tolerability as very good or good.	Vestweber 2009
medEctoin® Psoriasis Cream	N = 101 Prospective, observational clinical study	Significant improvement of Atopic dermatitis symptoms: Erythema, Hardening of the skin, Pruritus, Dryness and Desquamation.	Bitop internal report btph-005-2008
Dermaveel® (5.5% medEctoin®)	N = 242 Prospective, observational clinical study	Significant reduction of pruritus and sleep disorder. Very good safety profile. SCORAD reduction of 64.3%.	Wilkowska et al. 2015

## Improvement rate of Psoriasis symptoms



**Figure 1:**  
Improvement of psoriasis symptoms after 4 and 8 weeks.

**Reference:**  
Vestweber 2009.

# medEctoin® Sicca Eye Drops + HA 0.2%

BAT13



The tear film fulfills important functions for maintaining eye health. As a result of a damaged tear film or a lack of tear film fluid, inflammation can occur. This results in dryness, redness, itching and burning of the eyes. **medEctoin® Sicca Eye Drops + HA 0.2%** combine medEctoin® with hyaluronic acid and can significantly improve dry eye symptoms. They intensively moisturize the eyes and stabilize the lipid layer of the tear film to prevent further dehydration.



## TREATMENT:

Moisturizes dry and irritated eyes  
Reduces burning and itching



## PREVENTION:

Stabilizes the lipid layer of the tear film and reduces further dehydration  
Protects ocular cells from hyperosmolarity  
Also effective as a preventive treatment



## REGENERATION:

Aids cell regeneration



## SAFETY & USABILITY:

Suitable for contact lens wearers  
Suitable for children  
Suitable for very sensitive eyes  
Preservative-free

## INGREDIENTS:

medEctoin®, Sodium Hyaluronate, Sodium Chloride, Citrate Buffer, Water



## Medical Device Class:

IIa (MDD)



## Packaging:

0.35 ml solution in ampoules (SDU)  
10 ml in multi-dose dropper (OSD)



## Shelf Life:

30 Months

## Period after Opening:


SDU: N.a.

MDU: 6 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Eye Drops	N = 65 Non-interventional, comparator-controlled clinical trial	Significant improvement in Tear Break Up Time within 4 weeks vs. baseline; non-inferior to HA eye drops	Clinical study report btph-032- 2012-BAT04
medEctoin® Sicca Eye Drops	N = 60 Clinical, observational, two arm study	Significant improvement in dry eye symptoms in postmenopausal women and glaucoma patients	Veselovska et al. 2015
medEctoin® Sicca Eye Drops	N = 24 Prospective, clinical, observational study	Significant improvement of dry eye symptoms in patients with contact lens-associated dry eye	Veselovska 2016

## Decrease of dry eye symptoms



**Figure 1:**  
Decrease of all dry-eye symptoms between visit 1 and visit 2  
(formulation without HA).

**Reference:**  
btph-032-2012-BAT04

# medEctoin® Sicca Eye Drops

BAT04



Dry eye disease is one of the most common ocular discomforts today. One factor in the vicious circle of this disease is a hyperosmolar tear fluid which is caused by an increased evaporation of tears or a decreased tear production. Tear hyperosmolarity leads to irritations like burning, redness and itching of the eyes. **medEctoin® Sicca Eye Drops** alleviate dry eye symptoms and protect against hyperosmolarity to break down the vicious circle of keratoconjunctivitis sicca.

---



## TREATMENT:

Alleviates symptoms of dry eyes such as burning, dryness, itching, etc.

Reduces inflammation caused by an irritated or dry conjunctiva

Stabilizes the lipid layer of the tear film and reduces further dehydration



## PREVENTION:

Moisturizes dry eyes and prevents from further dehydration

Protects ocular cells from hyperosmolarity

Suitable for preventive use



## REGENERATION:

Supports the regeneration process of a dry and irritated conjunctiva



## SAFETY & USABILITY:

Suitable for contact lens wearers

Suitable for sensitive eyes

Suitable for children

Preservative-free

---

## INGREDIENTS:

medEctoin®, Hydroxyethyl Cellulose, Sorbitol, Citrate Buffer, Water



## Medical Device Class:

IIa (MDD)



## Packaging:

0.5 ml solution in ampoules (SDU)

10 ml in multi-dose dropper (OSD)



## Shelf Life:

SDU: 30 Months

MDU: 36 Months

## Period after Opening:


SDU: N.a.

MDU: 6 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Eye Drops	N = 65 Non-interventional, comparator-controlled clinical trial	Significant improvement in Tear Break Up Time within 4 weeks vs. baseline; non-inferior to HA eye drops	Clinical study report btph-032- 2012-BAT04
medEctoin® Sicca Eye Drops	N = 60 Clinical, observational, two arm study	Significant improvement in dry eye symptoms in postmenopausal women and glaucoma patients	Veselovska et al. 2015
medEctoin® Sicca Eye Drops	N = 24 Prospective, clinical, observational study	Significant improvement of dry eye symptoms in patients with contact lens-associated dry eye	Veselovska 2016

## Improvement of tear film stability



**Figure 1:**  
Improved tear film stability after treatment.

**Reference:**  
btph-032-2012-BAT04

# medEcto<sup>®</sup> Inflammation Reducing Eye Drops

EED01/03



Inflammatory diseases of the eyes are often characterized by symptoms like red, itchy, and watery eyes. Most OTC products used in this indication are pharmaceuticals with well-known side effects such as rebound effects from vasoconstrictors or increased intra-ocular pressure.

**medEcto<sup>®</sup> Inflammation Reducing Eye Drops** are clinically proven to reduce symptoms of inflamed eyes. They show a comparable reduction of epiphora to corticosteroids, without any negative side effects associated with their use.



## TREATMENT:

Quick reduction of symptoms like itching, tearing and irritation within 30 seconds

Alleviates symptoms such as burning, dryness, itching, redness, and foreign body sensation

Superior reduction of inflammatory mediators through cell stabilization by the medEcto<sup>®</sup> Hydro Complex



## REGENERATION:

Supports wound healing after ocular surgeries and/or injuries of the eyes

Improves cell regeneration

Stabilizes tear film and restores balanced tear production

Supports faster epithelization in early postoperative period

Transparency of cornea is regained faster after eye injury or surgery



## PREVENTION:

Moisturizes dry eyes and prevents further dehydration



## SAFETY & USABILITY:

Proven efficacy also in combination with antibiotic, antiseptic or other anti-inflammatory treatment

Suitable for sensitive eyes and contact lens wearers

Suitable for all ages

Preservative-free

Effect based on 100% natural ingredients

Efficacy clinically proven

## INGREDIENTS:

medEcto<sup>®</sup>, Hydroxyethyl Cellulose, Sodium Chloride, Citrate Buffer, Water



## Medical Device Class:

IIa (according to 93/42/EEC)



## Packaging:

0.5 ml solution in ampoules (SDU)

10 ml in multi-dose dropper (OSD or 3K\*)



## Shelf Life:

SDU: 30 months

MDU: 36 months

## Period after Opening:

SDU: N.a.


MDU: 6 months

\* For formulation EED01

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Inflammation Reducing Eye Drops	N = 26 Prospective, randomized, open-label, controlled clinical trial	Significant improvement in epiphora with no increase in intraocular pressure; effectiveness comparable to corticosteroids	Martinez et al. 2018
Various medEctoin® Eye Drops	Systematic review of 16 clinical trials, focused on efficacy and safety of medEctoin® Eye Drops	Effective alternative or add-on treatment for ocular irritation and inflammation through epithelial barrier stabilization by medEctoin® Eye Drops	Bilstein et al. 2021

## Reduction of Epiphora



**Figure 1:** Improvement of epiphora after 4 weeks of treatment.

**Reference:** Martinez et al. 2018.

# medEctoin® Eye Gel Drops

EED02



Inflammatory diseases of the eyes are often characterized by red, itchy and burning eyes. **medEctoin® Eye Gel Drops** intensely moisturize irritated eyes during day and night. The high viscosity results in a prolonged retention time of medEctoin® for an even better treatment and regeneration.



## TREATMENT:

- Calms and soothes irritated and tired eyes
- Intensive and longer moisturization of dry and irritated eyes due to prolonged retention time\*
- Alleviates allergic symptoms (red, itchy and watery eyes)
- Stabilizes the lipid layer of the tear film and reduces further dehydration
- Reduces burning, itching and foreign body sensation
- Protects ocular cells from hyperosmolarity due to effective water-binding capacity of medEctoin® Hydro Complex

\*compared to low-viscosity eye drops, based on pre-clinical data



## PREVENTION:

- Effective as preventive treatment
- Protects against harmful influences of allergens
- Reduces allergen induced inflammation of the conjunctiva
- Prevents eye irritations and forms a protective layer



## REGENERATION:

- Supports wound healing after ocular surgeries and/ or injuries of the eyes
- Supports the regeneration process of irritated and sensitive conjunctiva



## SAFETY & USABILITY:

- Suitable for children
- Suitable for sensitive eyes
- Suitable for contact lens wearers
- Preservative-free

## INGREDIENTS:

medEctoin®, Hydroxyethyl Cellulose, Sodium Chloride, Citrate Buffer, Water



## Medical Device Class:

IIa (MDD)



## Packaging:

5 ml or 10 ml in multi-dose dropper (OSD)



## Shelf Life:

5 ml: 24 months  
10 ml: 30 months


## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Eye Drops	N = 65 Non-interventional, comparator-controlled trial	Significant improvement in Tear Break Up Time within 4 weeks vs. baseline; non-inferior to HA eye drops	Clinical study report btph-032- 2012-BAT04
medEctoin® Sicca Eye Drops	N = 60 Clinical, observational, two arm study	Significant improvement in dry eye symptoms in postmenopausal women and glaucoma patients	Veselovska et al. 2015
medEctoin® Allergy Eye Drops 2%	N = 50 Non-interventional, randomized, controlled study	Immediate relief within 30 seconds post-CPT exposure; 87% reduction in irritation after 30 minutes	Clinical study report btph-015- 2018-AAT04- EES09

## Decrease of dry eye symptoms



**Figure 1:**  
Decrease of all dry-eye symptoms  
(formulation: medEctoin® Sicca Eye Drops)

**Reference:**  
btph-032-2012-BAT04.

# medEctoin® Vaginal Gel

EIC01



Vaginal atrophy is a discomforting clinical condition during and after menopause caused mainly by hormonal imbalance. Vaginal dryness is the most bothersome symptom of vaginal atrophy. The **medEctoin® Vaginal Gel** with 2% medEctoin® immediately moisturizes dry and irritated vaginal mucosa, relieving vaginal atrophy symptoms such as burning and itching with long-lasting effect. Irritations are reduced and regeneration of the intimate area is supported.



## PREVENTION:

Helps reduce inflammation of the vaginal mucosa

Immediately (10-15 minutes) hydrates dry and irritated vaginal mucosa and prevents further dehydration

Relieves symptoms of vaginal atrophy within 5 days of application, such as itching and burning and prevents worsening

Provides long-lasting moisturization of the vaginal mucosa

Reduces pain during sexual intercourse



## PREVENTION:

Reduces irritations of vaginal mucosa and prevents it if used regularly

Maintains pH balance inside the vagina, regular use helps maintain optimal vaginal milieu

\*tested according to ISO 19671:2018



## REGENERATION:

Supports the regeneration process of irritated vaginal mucosa

The medEctoin® Hydro Complex stabilizes the cell membranes of the mucosa, maintains hydration, and supports the regeneration process

Improves elasticity of the vaginal mucosa



## SAFETY & USABILITY:

Can be used together with systemic hormonal treatments

Compatible with natural latex, polyisoprene and polyurethane condoms\*

Gynecologically and dermatologically tested

Effects are based on 100 % natural ingredients

Suitable for daily use

Free from hormones, fragrances, mineral oils, dyes and alcohol

## INGREDIENTS:

medEctoin®, Hydroxyethyl Cellulose, Lactic Acid, Sodium Lactate, Sodium Benzoate, Propylene Glycol, Water.



## Medical Device Class:

I (MDD)



## Packaging:

30 ml or 50 ml Aluminium Tube with 2.5 ml applicator



## Shelf Life:

24 Months

## Period after Opening:

3 months

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Vaginal Gel	N = 155 Prospective, open label clinical study	Significant improvement of vaginal health index. Significant reduction of vaginal atrophy score. Immediate symptoms reduction within 15 min. Long-term effect up to 5 days.	btph-045-2022-EIC01  Clintrials.gov NCT04910906

## Improvement of Vaginal Atrophy Symptoms




Figure 1:  
Improvement of Vaginal Atrophy symptoms over time.

Reference:  
btph-045-2022-EIC01

# medEctoïn® Mouth Wash 2%

BCML03



medEctoïn® Mouth Wash 2% is specifically designed to support patients with a sensitive and compromised oral mucosa, especially during mucositis. Its advanced formulation with medEctoïn® provides intensive hydration, forms a protective barrier on the mucosal surface, and helps to alleviate sensations of burning, dryness, and irritation. By stabilizing the cell membranes and reducing external stress, it promotes oral comfort and resilience. Ideal for daily use to maintain the mucosal integrity in vulnerable patients.



## HYDRATION & COMFORT:

With 2% medEctoïn®, clinically proven to effectively reduce inflammation and provide long-lasting cell protection

Provides intensive, long-lasting hydration for dry and stressed oral mucosa and gums

Relieves burning, dryness, and irritation of the sensitive oral mucosa and gums

Forms a protective moisture barrier for long-lasting comfort

Soothes irritated oral mucosa and gums under challenging conditions

medEctoïn® supports the natural recovery of stressed oral mucosa and gums

The listed claims are suggestions only; customers must ensure compliance with applicable regulations in their country.



## ORAL CARE & PROTECTION:

Gently cleanses without irritants like alcohol or preservatives

Strengthens oral mucosa against dryness and external stressors

Recommended for oral discomfort in mucositis.



## NATURAL & SAFE:

Sterile product: Free from preservatives and safe for daily use on sensitive mucosa

Free from alcohol and coloring agents

## INGREDIENTS:

Aqua (Water), Ectoïn, Xylitol, Hydroxyethylcellulose, Disodium Phosphate



## Classification:

Cosmetic Product



## Packaging:

30 x 5 ml solution in ampoules (SDU)



## Shelf Life:

24 months


## Period after Opening:

N.a.

# Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Mouth Wash 2%	N = 45 Non interventional, comparator controlled clinical study	Significant reduction of symptoms of chemotherapy-induced oral mucositis.  80% of chemotherapy-patients with mucositis were entirely symptom- free after 3 weeks of treatment	Dao et al. 2018
medEctoin® Soft Lozenges	N = 90 Prospective, active-controlled clinical study	Significant improvement pain on swallowing, dry mouth and throat and reddening of the oral mucosa.  67.5% of patients attained a „very good“ health condition at the end of the study.	Dao et al. 2019
medEctoin® Mouth and Throat Spray	N = 95 Prospective, controlled clinical study	Treatment of acute laryngitis and/ or pharyngitis symptoms with the medEctoin® demonstrates superiority to saline lozenges in improving the general health condition of patients.	Müller et. al. 2016

## Effectiveness against dry mucosa



**Figure 4:**  
Reduced severity of symptoms in patients using  
medEctoin® Mouth and Throat Spray 1%.

**Reference:**  
Müller et al. 2016.

# ■ Get your next product with our full technical support



## Certification

With bitop's internationally well recognized ISO 13485 certification, you can trust that medEctoin® products meet the highest standards.



## Scientific Support

Our team provides in-depth scientific support, backed by years of research, to help you maximize the potential of medEctoin® in your products.



## Technical Documentation

bitop offers access to the technical documentation of its medical devices and the support of our experts, helping your internal due diligence to be completed in no time.



## Access to all Studies

bitop provides full access to a robust portfolio of clinical and scientific studies, giving you the data you need to support the efficacy and safety of medEctoin® in your products.



## Regulatory

As a leading expert for medEctoin®, we helped successfully register our products under 100+ different regulations.



## Audit

bitop offers complete transparency by offering you the exclusive right to perform regular audits at our production site, ensuring our processes meet your stringent quality and compliance requirements.

# Quality and Safety at bitop AG

At bitop AG, quality is our top priority. As an ISO 13485-certified manufacturer of high-grade raw materials and medical devices, we implement a robust, cross-departmental quality management system that meets international standards, guaranteeing both safety and reliability in every product—trusted by partners worldwide



## In-House Excellence: Ingredient Integrity

As a pioneering producer of lab-grown extremolytes, bitop enforces rigorous quality protocols:

**Purity Testing:** Ectoin® and Glycoin® undergo cutting-edge analytical testing to ensure they meet exact purity specs and are free from contaminants.

**Batch Release Testing:** Every production batch is comprehensively tested for stability, efficacy, and safety before release to the market.



## Finished Product Assurance

For medEctoin®-based medical devices and finished products, bitop ensures uncompromised quality through:

**Rigorous CMO Qualification:** Partnering only with Contract Manufacturing Organizations in Germany and Europe that are ISO 13485-certified and regularly audited for compliance.

**In-Process Quality Controls:** Continuous monitoring by CMOs throughout production to uphold regulatory and bitop's internal standards.

**Final Inspection by bitop:** Each completed product undergoes thorough scrutiny—including checks for sterility, microbial safety, accurate packaging and labeling, and overall conformity to specifications under ISO 13485



**Let's Grow Together**  
**Become a partner today**

**bitop**

The Ectoin® Company

bitop AG  
Carlo-Schmid-Allee 5  
DE-44263 Dortmund  
bitop@bitop.de  
www.bitop.de

